Aclaris Therapeutics, Inc. ACRS
3.92 USD -0.08 (-2.00%)
Regular-session close
3.76 -0.16 -4.08%
After hours · Nov 13, 7:01 PM ET
3.78 Day range 3.99
2.32 52-week range 6.53
- YTD
- +30.23%
- 1 year
- +68.97%
News
globenewswire.com Aclaris Therapeutics to Participate in the Jefferies Global Healthcare Conference WAYNE, Pa., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for…
defenseworld.net Aclaris Therapeutics (NASDAQ:ACRS) vs. Oncocyte (NASDAQ:IMDX) Financial Contrast Aclaris Therapeutics (NASDAQ: ACRS - Get Free Report) and Oncocyte (NASDAQ: IMDX - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two…
zacks.com Aclaris Therapeutics (ACRS) Reports Q3 Loss, Beats Revenue Estimates Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.12 per share a year ago.benzinga.com Aclaris Therapeutics Q3 EPS $(0.12) Beats $(0.16) Estimate, Sales $1.481M Beat $1.298M Estimate Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.16) by 25 percent. This is unchanged from the same period last year.…
globenewswire.com Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical Update - Initiation of Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus Expected in Fourth Quarter of 2026 - - Timeline Reaffirmed for Top Line Results from Phase 2 ADMIRATION Trial of Bosakitug…benzinga.com Canaccord Genuity Maintains Buy on Aclaris Therapeutics, Raises Price Target to $13 Canaccord Genuity analyst Edward Nash maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and raises the price target from $10 to $13.
benzinga.com Wedbush Maintains Outperform on Aclaris Therapeutics, Lowers Price Target to $8 Wedbush analyst Martin Fan maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Outperform and lowers the price target from $10 to $8.
benzinga.com HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $16 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and maintains $16 price target.
marketbeat.com Aclaris Therapeutics ATI-052 Posts Early Eczema, Asthma Signals in Phase 1b Aclaris Therapeutics NASDAQ: ACRS reported Phase 1b proof-of-concept results for ATI-052, its bispecific antibody designed to inhibit thymic stromal lymphopoietin (TSLP) and IL-4 receptor alpha, in…
benzinga.com Aclaris Says Early Data Validates Dual-Target Approach for Eczema, Asthma Drug Aclaris Therapeutics announces positive Phase 1b trial data for ATI-052 in eczema and asthma alongside a $50 million public financing round.
seekingalpha.com Aclaris Therapeutics, Inc. (ACRS) Discusses ATI-052 Proof-of-Concept Results in Atopic Dermatitis and Asthma Transcript Aclaris Therapeutics, Inc. (ACRS) Discusses ATI-052 Proof-of-Concept Results in Atopic Dermatitis and Asthma Transcript
benzinga.com Whirlpool Posts Downbeat Q3 Results, Joins HSBC, Hilton Hotels And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. futures rose, but Whirlpool plunged after a major earnings miss and lowered guidance; HSBC, Armstrong World and others also fell premarket.benzinga.com Aclaris Therapeutics Prices $50M Offering Of 7,785,714 Shares And Warrants To Purchase 6.5M Shares At $3.50/Unit Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced the pricing of an…
globenewswire.com Aclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded Warrants WAYNE, Pa., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for…
globenewswire.com Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis (AD) and Asthma Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis
defenseworld.net Aclaris Therapeutics, Inc. (ACRS) – What Are Analysts Saying About This Stock? Shares of Aclaris Therapeutics, Inc. (NASDAQ: ACRS - Get Free Report) have earned an average recommendation of "Buy" from the nine brokerages that are covering the firm, Marketbeat Ratings reports.…
zacks.com Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year? Here is how Aclaris Therapeutics (ACRS) and Glaukos (GKOS) have performed compared to their sector so far this year.benzinga.com Truist Financial, Regions Financial And Other Big Stocks Moving Lower In Friday’s Pre-Market Session U.S. stock futures mixed; Truist slips after mixed results, while Telkom Indonesia, Loma Negra, Omeros and others fall premarket.
benzinga.com Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket Alcoa shares rose after Q3 earnings beat estimates; Rubico and others surged, while Nuburu, Jaguar Health and other stocks fell premarket.
benzinga.com Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session U.S. stock futures fell, with Dow futures down 450 points. Argenx sank 8.7% after a Sjögren’s trial was halted for futility; others also slid.
zacks.com Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock? Aclaris (ACRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Circle8 Group (NASDAQ:CIRC) stock moved upwards by 14.6% to $0.57 during Monday's after-market session. The company's market cap stands at $50.2 million. Eocene (NASDAQ:EOCN) shares rose…
globenewswire.com Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference WAYNE, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for…benzinga.com Canaccord Genuity Initiates Coverage On Aclaris Therapeutics with Buy Rating, Announces Price Target of $10 Canaccord Genuity analyst Edward Nash initiates coverage on Aclaris Therapeutics (NASDAQ:ACRS) with a Buy rating and announces Price Target of $10.
benzinga.com Vipshop, Gorilla Technology Group And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. stock futures rise, Nasdaq 100 gains 200 points. Vipshop shares fall 4.9% after reporting Q2 earnings below expectations. Other stocks dip in pre-market trading.
benzinga.com Why Cadeler Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket Shares of Cadeler A/S (NYSE: CDLR) surged in pre-market trading after reporting strong financial results for the first half of 2026. Revenue and profit increased significantly, and full-year guidance…
defenseworld.net Deutsche Bank AG Makes New Investment in Aclaris Therapeutics, Inc. $ACRS Deutsche Bank AG purchased a new stake in Aclaris Therapeutics, Inc. (NASDAQ: ACRS) in the second quarter, according to the company in its most recent filing with the Securities and Exchange…
zacks.com Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade The consensus price target hints at a 69.2% upside potential for Aclaris (ACRS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate…
globenewswire.com Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP) WAYNE, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for…
zacks.com Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.13 per share a year ago.benzinga.com Aclaris Therapeutics Q2 EPS $(0.15) Beats $(0.16) Estimate, Sales $1.629M Beat $1.383M Estimate Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.16) by 6.25 percent. This is a 15.38 percent decrease over losses of…
globenewswire.com Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update - Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Validate Potential Best-in-Class Potency Advantage and Opportunity for Extended Dosing - - Timelines Reaffirmed for Upcoming Top Line…
zacks.com Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength? Aclaris (ACRS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Alzamend Neuro (NASDAQ:ALZN) stock increased by 12.9% to $1.35 during Tuesday's after-market session. The company's market cap stands at $4.4 million. Vivos Therapeutics (NASDAQ:VVOS) shares…
marketbeat.com 3 Penny Stocks Under $5 Backed by Real Revenue Growth Investing in penny stocks requires significant conviction. Many of the companies in this group are purely “story stocks.
benzinga.com SL Science Holding, Alamos Gold And Other Big Stocks Moving Lower In Monday’s Pre-Market Session U.S. stock futures mixed. SL Science shares fall 11.4% after reporting financial results. Other stocks also down in pre-market trading.
marketbeat.com 3 Penny Stocks Under $5 Backed by Real Revenue Growth Investing in penny stocks requires significant conviction. Many of the companies in this group are purely “story stocks.
benzinga.com This Piper Sandler Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations From Tuesday Top Wall Street analysts begin coverage of Aclaris Therapeutics, Orion Group Holdings, and Take-Two Interactive.benzinga.com Aclaris Therapeutics Q1 EPS $(0.15), Inline, Sales $1.996M Beat $1.322M Estimate Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.15) per share which met the analyst consensus estimate. This is a 25 percent decrease over losses of $(0.12) per share from the…
benzinga.com Piper Sandler Maintains Overweight on Aclaris Therapeutics, Raises Price Target to $11 Piper Sandler analyst Biren Amin maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Overweight and raises the price target from $7 to $11.
benzinga.com This Applied Materials Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Citations for AMAT, BMEA, ACRS, KALU, SION.benzinga.com Guggenheim Initiates Coverage On Aclaris Therapeutics with Buy Rating, Announces Price Target of $12 Guggenheim analyst Seamus Fernandez initiates coverage on Aclaris Therapeutics (NASDAQ:ACRS) with a Buy rating and announces Price Target of $12.
benzinga.com Wedbush Maintains Outperform on Aclaris Therapeutics, Raises Price Target to $10 Wedbush analyst Martin Fan maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Outperform and raises the price target from $8 to $10.
benzinga.com Aclaris Therapeutics Announces Top Line Results From Its Phase 1a Single And Multiple Ascending Dose Trial Of Its Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 And The Selection Of Lichen Llanus As The lead Indication For Its Selective ITK/JAK3 Inhibitor ATI-2138 "These results validate that ATI-052 is a highly potent and well tolerated bispecific antibody that has the potential to be highly effective in a variety of inflammatory and immunological disorders,"…
benzinga.com Aclaris Therapeutics to Reveal Clinical Update On Key Biologic And Oral Inhibitor Programs on April 28, 2026 Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it will…
benzinga.com Oppenheimer Initiates Coverage On Aclaris Therapeutics with Outperform Rating, Announces Price Target of $10 Oppenheimer analyst Jeff Jones initiates coverage on Aclaris Therapeutics (NASDAQ:ACRS) with a Outperform rating and announces Price Target of $10.
benzinga.com Wedbush Reiterates Outperform on Aclaris Therapeutics, Maintains $8 Price Target Wedbush analyst Martin Fan reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Outperform and maintains $8 price target.
benzinga.com Aclaris Therapeutics Presents Additional Results From Phase 2a Trial Of ATI-2138, Potent And Selective Investigational Oral Covalent Inhibitor Of ITK And JAK3, At 2026 AAD Annual Meeting - Participants with Atopic Dermatitis Receiving ATI-2138 Experienced Improvements in Key Clinical Measures including Disease Severity, Itch, and Quality of Life -WAYNE, Pa., March 27, 2026 (GLOBE…
benzinga.com Aclaris Therapeutics To Present Results From Open-Label Phase 2a Trial Of ATI-2138, Investigational Oral Covalent Inhibitor Of Interleukin-2-ITK And JAK3, At 2026 AAD Annual Meeting Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that an ePoster…
benzinga.com HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $16 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and maintains $16 price target.
